Getting personal with melanoma

Helen Heslop

doi:10.1158/1078-0432.CCR-11-0841

Getting personal with melanoma

Helen Heslop

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

Long-term follow-up of patients with metastatic melanoma who received adoptive immunotherapy with autologous tumor infiltrating lymphocytes shows that patients who attained complete remission had durable responses, with 19 of 20 such patients remaining in remission from 3 to 7 years or more.

Original language	English (US)
Pages (from-to)	4189-4191
Number of pages	3
Journal	Clinical Cancer Research
Volume	17
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.CCR-11-0841
State	Published - Jul 1 2011

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-11-0841

Cite this

@article{4039f4163ed84d678bf5ac9b046799e6,

title = "Getting personal with melanoma",

abstract = "Long-term follow-up of patients with metastatic melanoma who received adoptive immunotherapy with autologous tumor infiltrating lymphocytes shows that patients who attained complete remission had durable responses, with 19 of 20 such patients remaining in remission from 3 to 7 years or more.",

author = "Helen Heslop",

year = "2011",

month = jul,

day = "1",

doi = "10.1158/1078-0432.CCR-11-0841",

language = "English (US)",

volume = "17",

pages = "4189--4191",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - Getting personal with melanoma

AU - Heslop, Helen

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Long-term follow-up of patients with metastatic melanoma who received adoptive immunotherapy with autologous tumor infiltrating lymphocytes shows that patients who attained complete remission had durable responses, with 19 of 20 such patients remaining in remission from 3 to 7 years or more.

AB - Long-term follow-up of patients with metastatic melanoma who received adoptive immunotherapy with autologous tumor infiltrating lymphocytes shows that patients who attained complete remission had durable responses, with 19 of 20 such patients remaining in remission from 3 to 7 years or more.

UR - http://www.scopus.com/inward/record.url?scp=79960316555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960316555&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-0841

DO - 10.1158/1078-0432.CCR-11-0841

M3 - Comment/debate

C2 - 21712453

AN - SCOPUS:79960316555

VL - 17

SP - 4189

EP - 4191

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -

Getting personal with melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this